Axonics to Report Third Quarter 2023 Financial Results on October 30
02 10월 2023 - 7:00PM
Business Wire
Axonics, Inc. (Nasdaq: AXNX), a global medical technology
company that is developing and commercializing novel products for
the treatment of bladder and bowel dysfunction, is scheduled to
report third quarter 2023 financial results after the close of
trading on Monday, October 30.
Axonics will host a conference call at 4:30 p.m. Eastern Time to
discuss financial results. To access the conference call by
telephone, interested parties may register at the following link:
Axonics 3Q23 registration.
For those not planning to ask a question, the company recommends
accessing the conference call by webcast at the following link:
Axonics 3Q23 webcast. A replay of the webcast will be archived in
the Events section of the Axonics investor relations website.
About Axonics
Axonics is a global medical technology company that is
developing and commercializing novel products for adults with
bladder and bowel dysfunction. Axonics recently ranked No. 2 on the
2023 Financial Times ranking of the fastest growing companies in
the Americas and No. 4 on the 2022 Deloitte Technology Fast
500.
Axonics® sacral neuromodulation systems provide adults with
overactive bladder and/or fecal incontinence with long-lived, easy
to use, safe, clinically effective therapy. Bulkamid®, the
company’s best-in-class urethral bulking hydrogel, provides safe
and durable symptom relief to women with stress urinary
incontinence. In the U.S., moderate to severe urinary incontinence
affects an estimated 28 million women and fecal incontinence
affects an estimated 19 million adults. For more information, visit
www.axonics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231002975346/en/
Axonics contact: Neil Bhalodkar 949-336-5293
IR@axonics.com
Axonics (NASDAQ:AXNX)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Axonics (NASDAQ:AXNX)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024